ROLE OF PET CT IN RESPONSE EVALUATION FOLLOWING NEOADJUVANT THERAPY AND ASSESSMENT OF DISTANT METASTSASIS IN PATIENTS WITH CARCINOMA GALLBLADDER

not applicable0 个研究点目标入组 40 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•All patients with gall bladder cancer, who are being administered neoadjuvant therapy.
•All patients with gallbladder cancer who are being planned for surgery.
•All patients with incidentally detected carcinoma gallbladder who are being planned for surgery.
•Ability to understand and willingness to sign a written informed consent

•a)Patient refuses consent.
•b)Poor performance status (ECOG â?? 3 and 4)
•c) Major co-morbid conditions such as cirrhosis, renal failure, uncontrolled hypertension or cardiac failure .
•d)Patients who have received chemotherapy/ radiotherapy within 12 months prior to study entry.
•e) Any evidence of metastasis to distant organs (liver, lung, peritoneum,brain, bone etc).
•f) Non-contiguous liver metastasis (M1 disease).
•g) Major vascular involvement such as proper hepatic artery involvement and main portal vein involvement (T4 â?? inoperable disease).
•h) Periaortic, Pericaval, Superior mesenteric artery and/or Celiac artery lymph node involvement (N2 disease) â?? confirmed by

发起方